|
|||
 |
|||
|
Arimidex (anastrozole) is approved for the initial treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and for the treatment of postmenopausal women with advanced breast cancer that has progressed following treatment with tamoxifen. Patients with hormone receptor-negative disease and patients who did not previously respond to tamoxifen therapy rarely responded to Arimidex. Understanding Arimidex important information prior to taking the drug can help ensure a safe and successful treatment process. The medication may not be appropriate for women who have osteoporosis or women who are breastfeeding. It likely will not be given to a woman who is pregnant. Arimidex important information also extend to people who are allergic to any ingredients used to make the drug. Arimidex won't work on hormone-receptor-negative breast cancer. Arimidex shouldn't be taken at the same time as tamoxifen. Users should be informed that Arimidex lowers the level of estrogen. This may lead to a loss of the mineral content of bones, which might decrease bone strength. A possible consequence of decreased mineral content of bones is an increase in the risk of fractures. Also an increased level of cholesterol might be seen while receiving Arimidex. In women with pre-existing ischemic heart disease, an increased incidence of ischemic cardiovascular events was observed with Arimidex in the trial (17% of patients on Arimidex and 10% of patients on tamoxifen). Consider risk and benefits of Arimidex therapy in patients with pre-existing ischemic heart disease. |
|||
|
|||
|
|||
|
|||
|
